Brief: Polyphor: Protocol Agreement With FDA For Second Pivotal Phase III Study Of Murepavadin

Spexis AG

24/10/2018 06:04

Oct 24 (Reuters) - Polyphor AG  POLN.S :
    * EQS-ADHOC: POLYPHOR ANNOUNCES PROTOCOL AGREEMENT WITH THE FDA FOR THE SECOND PIVOTAL PHASE
III
STUDY OF MUREPAVADIN
    * EXPECTS TO RECRUIT FIRST PATIENT BY Q119

Source text for Eikon:  ID:nEQ4tkq00a 
Further company coverage:  POLN.S 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))